Your browser is no longer supported. Please, upgrade your browser.
Settings
CYTK Cytokinetics, Incorporated daily Stock Chart
CYTK [NASD]
Cytokinetics, Incorporated
Index- P/E- EPS (ttm)-2.30 Insider Own0.40% Shs Outstand55.69M Perf Week-5.91%
Market Cap381.48M Forward P/E- EPS next Y-1.76 Insider Trans-12.90% Shs Float50.85M Perf Month-2.70%
Income-120.30M PEG- EPS next Q-0.52 Inst Own73.40% Short Float5.10% Perf Quarter-17.96%
Sales22.10M P/S17.26 EPS this Y-769.10% Inst Trans2.14% Short Ratio6.32 Perf Half Y-23.03%
Book/sh0.95 P/B7.21 EPS next Y11.10% ROA- Target Price14.00 Perf Year-22.16%
Cash/sh3.78 P/C1.81 EPS next 5Y15.00% ROE- 52W Range5.90 - 10.26 Perf YTD8.39%
Dividend- P/FCF- EPS past 5Y-2.40% ROI-80.10% 52W High-33.20% Beta2.29
Dividend %- Quick Ratio10.60 Sales past 5Y12.10% Gross Margin- 52W Low16.10% ATR0.41
Employees137 Current Ratio10.60 Sales Q/Q71.00% Oper. Margin- RSI (14)47.91 Volatility4.68% 6.56%
OptionableYes Debt/Eq0.80 EPS Q/Q33.10% Profit Margin- Rel Volume0.45 Prev Close7.02
ShortableYes LT Debt/Eq0.73 EarningsFeb 14 AMC Payout- Avg Volume410.72K Price6.85
Recom- SMA200.89% SMA50-3.71% SMA200-12.86% Volume186,180 Change-2.42%
Sep-21-18Initiated Cantor Fitzgerald Overweight
Sep-10-18Resumed Morgan Stanley Equal-Weight $10
Nov-22-17Reiterated Morgan Stanley Overweight $25 → $17
Nov-22-17Downgrade Needham Strong Buy → Buy $22 → $12
Nov-21-17Reiterated H.C. Wainwright Buy $26 → $17
Jul-31-17Initiated Morgan Stanley Overweight $24
Mar-08-17Initiated Rodman & Renshaw Buy $25
Feb-06-17Upgrade Needham Buy → Strong Buy $17 → $22
Dec-16-16Initiated Cantor Fitzgerald Overweight $21
Jul-28-16Reiterated Needham Buy $15 → $17
Nov-10-15Reiterated FBR Capital Outperform $14 → $24
Nov-09-15Reiterated ROTH Capital Buy $18 → $22
Jul-24-15Reiterated MLV & Co Buy $9 → $14
Dec-31-14Reiterated ROTH Capital Buy $13 → $18
Nov-04-14Upgrade MLV & Co Hold → Buy $9
Apr-28-14Reiterated Needham Buy $25 → $15
Apr-25-14Downgrade MLV & Co Buy → Hold $26 → $5
Jun-26-13Reiterated MLV & Co Buy $24 → $26
Jul-02-12Initiated Needham Buy $2.50
Oct-13-11Initiated Rodman & Renshaw Mkt Outperform $4
Jan-04-19 07:24AM  Could Cytokinetics, Incorporateds (NASDAQ:CYTK) Investor Composition Influence The Stock Price? Simply Wall St. +6.28%
Dec-22-18 02:51AM  Hedge Funds Are Dumping Cytokinetics, Inc. (CYTK) Insider Monkey
Dec-10-18 07:30AM  Cytokinetics Announces New Data Presented at the International Symposium on ALS/MND GlobeNewswire
Dec-05-18 07:30AM  Cytokinetics Announces Initiation of Phase 1 Clinical Trial of CK-3773274, a Cardiac Myosin Inhibitor GlobeNewswire
Dec-03-18 07:57AM  Jim Cramer Gives His Opinion On Netflix, Kraft Heinz And More Benzinga
Nov-27-18 08:00AM  Analysis: Positioning to Benefit within Abeona Therapeutics, Great Lakes Dredge & Dock, Imprimis Pharmaceuticals, Alliant Energy, Cytokinetics, and Aurinia Pharmaceuticals Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
07:30AM  Cytokinetics Completes Enrollment in FORTITUDE-ALS, Phase 2 Clinical Trial of Reldesemtiv in Patients With ALS GlobeNewswire
Nov-26-18 04:00PM  Cytokinetics Announces Five Presentations at the International Symposium on ALS/MND GlobeNewswire +5.36%
Nov-20-18 04:40AM  Cytokinetics Sees Hammer Chart Pattern: Time to Buy? Zacks
Nov-07-18 04:00PM  Cytokinetics to Participate in Upcoming Investor Conferences GlobeNewswire +7.92%
Nov-05-18 07:10AM  Edited Transcript of CYTK earnings conference call or presentation 1-Nov-18 8:30pm GMT Thomson Reuters StreetEvents -7.57%
Nov-01-18 05:10PM  Cytokinetics (CYTK) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:08PM  Cytokinetics: 3Q Earnings Snapshot Associated Press
04:00PM  Cytokinetics, Inc. Reports Third Quarter 2018 Financial Results GlobeNewswire
Oct-18-18 04:00PM  Cytokinetics to Announce Third Quarter Results on November 1, 2018 GlobeNewswire -6.83%
Oct-16-18 07:30AM  Cytokinetics Unveils Expanded Development Pipeline and Provides Key Updates on Late-Stage Clinical Research Programs at R&D Day GlobeNewswire +13.65%
Oct-09-18 08:00AM  Report: Developing Opportunities within Denny's, Cytokinetics, Beazer Homes, Heidrick & Struggles International, Equity Commonwealth, and Spok Future Expectations, Projections Moving into 2018 GlobeNewswire
Oct-08-18 07:30AM  The Week Ahead In Biotech: Conferences, Clinical Trial Results And IPOs Benzinga
Oct-05-18 07:30AM  Cytokinetics and Astellas Provide Updates Regarding Collaborative Skeletal Muscle Program GlobeNewswire
Oct-02-18 04:00PM  Cytokinetics to Host R&D Day on October 16, 2018 GlobeNewswire
Oct-01-18 09:46AM  Cytokinetics Incorporated (NASDAQ:CYTK): Risks You Need To Consider Before Buying Simply Wall St. -8.53%
Sep-25-18 04:00PM  Cytokinetics to Present at the Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-21-18 03:32PM  Cantor Fitzgerald's 7 Buys For 7 Biotechs Benzinga
Sep-16-18 02:22PM  The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs Benzinga
Sep-05-18 04:00PM  Cytokinetics to Present at the Morgan Stanley Global Healthcare Conference GlobeNewswire
Aug-28-18 08:30AM  Cytokinetics Awards Inaugural Communications Fellowship To The ALS Association Golden West Chapter GlobeNewswire
Aug-01-18 09:39AM  Cytokinetics Downgraded On Data Delay Benzinga
08:10AM  Market Trends Toward New Normal in US Foods Holding, Limelight Networks, Ladenburg Thalmann Financial Services, MPLX LP, Cytokinetics, and FuelCell Energy Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Jul-27-18 11:19AM  Edited Transcript of CYTK earnings conference call or presentation 26-Jul-18 8:30pm GMT Thomson Reuters StreetEvents -5.70%
Jul-26-18 05:19PM  Cytokinetics: 2Q Earnings Snapshot Associated Press
04:00PM  Cytokinetics, Inc. Reports Second Quarter 2018 Financial Results GlobeNewswire
Jul-12-18 04:00PM  Cytokinetics to Announce Second Quarter Results on July 26, 2018 GlobeNewswire
Jun-16-18 11:40AM  Cytokinetics Announces Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy Presented at the 2018 Annual Cure SMA Conference GlobeNewswire
Jun-13-18 04:00PM  Cytokinetics to Present at the JMP Securities Life Sciences Conference GlobeNewswire
Jun-11-18 10:34AM  3 Biotechs with Upcoming Data to Watch SmarterAnalyst +5.85%
Jun-08-18 04:00PM  Cytokinetics Announces Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy to be Presented at the 2018 Annual Cure SMA Conference on June 16, 2018 GlobeNewswire
Jun-05-18 12:02PM  June Best Growth Stocks Simply Wall St. +9.15%
08:31AM  Are Options Traders Betting on a Big Move in Cytokinetics (CYTK) Stock? Zacks
May-17-18 07:30AM  Cytokinetics and Cure SMA Renew and Expand Partnership to Advance Education and Awareness of SMA GlobeNewswire
May-10-18 04:00PM  Cytokinetics to Hold Annual Meeting of Stockholders GlobeNewswire
May-01-18 07:30AM  Cytokinetics and the ALS Association Renew Partnership to Advance the Fight Against ALS GlobeNewswire
Apr-30-18 07:30AM  Blog Exposure - Zealands End-of-Phase-2 Meeting with FDA Confirmed the Path Forward for Phase-3 Program of Glepaglutide for Short Bowel Syndrome ACCESSWIRE
Apr-29-18 11:40PM  Edited Transcript of CYTK earnings conference call or presentation 26-Apr-18 8:30pm GMT Thomson Reuters StreetEvents
Apr-27-18 05:06AM  Cytokinetics: 1Q Earnings Snapshot Associated Press +12.34%
Apr-26-18 04:00PM  Cytokinetics, Inc. Reports First Quarter 2018 Financial Results GlobeNewswire +6.21%
08:02AM  Is Cytokinetics Incorporated (NASDAQ:CYTK) Worth $7.25 Based On Intrinsic Value? Simply Wall St.
Apr-24-18 07:30AM  Cytokinetics Announces Presentation of Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy at the 2018 Annual Cure SMA Conference GlobeNewswire
Apr-12-18 04:00PM  Cytokinetics to Announce First Quarter Results on April 26, 2018 GlobeNewswire
Mar-05-18 04:00PM  Cytokinetics to Present at March Investor Conferences GlobeNewswire +5.03%
Feb-28-18 07:30AM  Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day GlobeNewswire
Feb-16-18 03:35PM  Edited Transcript of CYTK earnings conference call or presentation 15-Feb-18 9:30pm GMT Thomson Reuters StreetEvents -7.23%
07:40AM  Market Trends Toward New Normal in Tile Shop Holdings, Cytokinetics, Limelight Networks, CatchMark Timber Trust, Global Payments, and Charles River Laboratories International Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Feb-15-18 04:34PM  Cytokinetics reports 4Q loss Associated Press
04:00PM  Cytokinetics, Inc. Reports Fourth Quarter 2017 Financial Results GlobeNewswire
12:00PM  Cytokinetics, Incorporated to Host Earnings Call ACCESSWIRE
10:29AM  What You Must Know About Cytokinetics Incorporateds (NASDAQ:CYTK) Major Investors Simply Wall St.
09:29AM  Cytokinetics Earnings Outlook Benzinga
Feb-14-18 04:00PM  Cytokinetics to Present at the RBC Capital Markets Global Healthcare Conference GlobeNewswire
Feb-12-18 07:30AM  Cytokinetics Names Robert Califf, M.D., to Board of Directors GlobeNewswire
Feb-02-18 04:00PM  Cytokinetics to Announce Fourth Quarter Results on February 15, 2018 GlobeNewswire
Jan-03-18 07:30AM  Cytokinetics Announces Progress Against Vision 2020 GlobeNewswire
Dec-08-17 04:20PM  Cytokinetics Announces Presentation of Results From VITALITY-ALS at 28th International Symposium on ALS/MND GlobeNewswire
Dec-01-17 04:00PM  Cytokinetics Announces Results of VITALITY-ALS to be Presented at the International Symposium on ALS/MND GlobeNewswire
08:00AM  Investor Expectations to Drive Momentum within CatchMark Timber Trust, Global Payments, Charles River Laboratories International, Tile Shop Hldgs, Cytokinetics, and Limelight Networks Discovering Underlying Factors of Influence GlobeNewswire
Nov-30-17 07:30AM  New Publication Summarizes Phase 1 Studies of CK-2127107 Showing Tolerability and Amplification of Skeletal Muscle Response to Nerve Activation GlobeNewswire +9.55%
07:30AM  New Publication Shows Respiratory Decline Correlated With Disease Progression in People Living With ALS GlobeNewswire
Nov-27-17 01:02PM  ETFs with exposure to Cytokinetics, Inc. : November 27, 2017 Capital Cube
Nov-22-17 07:35AM  Biotech Stock Roundup: RARE drug Gets FDA Nod, Acorda, Cytokinetics Hit by Pipeline Setbacks Zacks
Nov-21-17 02:48PM  Cytokinetics CEO: Optimism still there despite ALS drug s... CNBC Videos -25.68%
11:04AM  Cytokinetics Crumbles on Late-Stage Results 24/7 Wall St.
10:56AM  Cytokinetics, Incorporated: Buy the Dip or Pump the Brakes? SmarterAnalyst
09:47AM  Why Is Cytokinetics Plunging Today? Benzinga
09:39AM  Cytokinetics, Inc. (CYTK) Stock Gets Whacked on Disappointing Clinical Results in ALS SmarterAnalyst
09:27AM  Cytokinetics Shares Plunge on Study Results for ALS Drug -- Biotech Movers TheStreet.com
08:46AM  Cytokinetics shares drop 31% on late-stage ALS drug failure MarketWatch
07:40AM  Cytokinetics' neuro-degenerative drug fails late-stage trial Reuters
07:30AM  Cytokinetics Announces Negative Results From VITALITY-ALS GlobeNewswire
Nov-17-17 08:40AM  Is the Options Market Predicting a Spike in Cytokinetics (CYTK) Stock? Zacks +5.83%
Nov-14-17 09:09AM  Is It Too Late To Buy Cytokinetics Incorporated (CYTK)? Simply Wall St.
Nov-13-17 02:10PM  Cytokinetics Announces Additional Results From COSMIC-HF at the American Heart Association Scientific Sessions 2017 GlobeNewswire -7.57%
Nov-08-17 05:53PM  ETFs with exposure to Cytokinetics, Inc. : November 8, 2017 Capital Cube
Nov-07-17 08:03AM  Cytokinetics, Inc. :CYTK-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017 Capital Cube
Nov-06-17 04:46PM  Edited Transcript of CYTK earnings conference call or presentation 26-Oct-17 8:30pm GMT Thomson Reuters StreetEvents -5.88%
04:20PM  Cytokinetics Announces Additional Results From COSMIC-HF to Be Presented at the American Heart Association Scientific Sessions 2017 GlobeNewswire
Oct-30-17 10:58AM  Cytokinetics, Inc.: Leads amongst peers with strong fundamentals Capital Cube
Oct-26-17 05:47PM  Cytokinetics reports 3Q loss Associated Press
04:00PM  Cytokinetics, Inc. Reports Third Quarter 2017 Financial Results GlobeNewswire
11:03AM  Cytokinetics, Inc. Value Analysis (NASDAQ:CYTK) : October 26, 2017 Capital Cube
09:15AM  Cytokinetics, Incorporated to Host Earnings Call ACCESSWIRE
Oct-25-17 08:15AM  Cytokinetics, Inc. breached its 50 day moving average in a Bearish Manner : CYTK-US : October 25, 2017 Capital Cube
Oct-12-17 04:00PM  Cytokinetics to Announce Third Quarter Results on October 26, 2017 GlobeNewswire
Oct-09-17 08:58AM  Implied Volatility Surging for Cytokinetics (CYTK) Stock Options Zacks
Sep-19-17 07:30AM  Cytokinetics Announces Dosing of First Patient in Japan in GALACTIC-HF, Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure GlobeNewswire
Sep-18-17 07:30AM  Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at the HFSA 21st Annual Scientific Meeting GlobeNewswire
Sep-15-17 08:43AM  Options Traders Expect Huge Moves in Cytokinetics (CYTK) Stock Zacks
Sep-11-17 04:00PM  Cytokinetics Announces Additional Results From COSMIC-HF to be Presented at the HFSA 21st Annual Scientific Meeting GlobeNewswire
Sep-07-17 12:54PM  ETFs with exposure to Cytokinetics, Inc. : September 7, 2017 Capital Cube
Sep-05-17 04:00PM  Cytokinetics to Present at September Investor Conferences GlobeNewswire
Aug-29-17 08:38AM  Cytokinetics, Inc. breached its 50 day moving average in a Bullish Manner : CYTK-US : August 29, 2017 Capital Cube +5.58%
Aug-21-17 04:05PM  ETFs with exposure to Cytokinetics, Inc. : August 21, 2017 Capital Cube
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. The company's drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in phase III clinical trials in patients with heart failure; and reldesemtiv, a fast skeletal muscle activator, which is in two phase II clinical trials in patients with spinal muscular atrophy and amyotrophic lateral sclerosis. It also develops reldesemtiv that is in phase II clinical trials in patients with chronic obstructive pulmonary disease, as well as in phase Ib clinical trials in elderly subjects with limited mobility. The company has strategic alliances with Astellas Pharma Inc. and Amgen Inc. The company was founded in 1997 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Malik Fady IbrahamEVP Research & DevelopmentJan 10Sale7.311,50010,96585,567Jan 11 07:00 PM
Blum Robert IPresident & CEOJan 04Sale7.114,00028,432148,022Jan 04 05:08 PM
Blum Robert IPresident & CEODec 06Sale7.504,00029,988152,022Dec 07 04:57 PM
Malik Fady IbrahamEVP Research & DevelopmentDec 06Sale7.381,50011,07087,067Dec 07 04:56 PM
Blum Robert IPresident & CEONov 05Sale7.114,00028,446156,022Nov 06 11:41 AM
Malik Fady IbrahamEVP Research & DevelopmentNov 01Sale6.681,50010,02088,567Nov 02 05:47 PM
Blum Robert IPresident & CEOOct 05Sale8.794,00035,178160,022Oct 05 07:23 PM
Malik Fady IbrahamEVP Research & DevelopmentOct 04Sale9.141,50013,71090,067Oct 05 11:36 AM
Malik Fady IbrahamEVP Research & DevelopmentSep 06Sale8.001,50012,00091,567Sep 07 04:12 PM
Blum Robert IPresident & CEOSep 05Sale7.944,00031,769164,022Sep 07 04:11 PM
Blum Robert IPresident & CEOAug 03Sale6.654,00026,582168,022Aug 03 05:21 PM
Malik Fady IbrahamEVP Research & DevelopmentAug 02Sale6.851,50010,27593,067Aug 03 05:14 PM
Blum Robert IPresident & CEOJul 05Sale9.094,00036,372172,022Jul 06 04:33 PM
Malik Fady IbrahamEVP Research & DevelopmentJul 05Sale9.051,50013,57594,567Jul 06 04:33 PM
Malik Fady IbrahamEVP Research & DevelopmentJun 07Sale8.953,00026,85096,067Jun 07 08:15 PM
Blum Robert IPresident & CEOJun 05Sale8.284,00033,116176,022Jun 05 06:11 PM
Blum Robert IPresident & CEOMay 04Sale8.384,00033,505180,022May 04 06:08 PM
Blum Robert IPresident & CEOApr 05Sale7.524,00030,090182,701Apr 06 06:01 PM